Consensus Mineralys Therapeutics, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 12:17:50 2024-05-13 pm EDT			5-day change	1st Jan Change
13.16 ^USD	-2.66%		-4.69%	+52.38%

May. 09	Transcript : Mineralys Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

0fd80d9c.Z-87b4_kLclJ9lzIPGYpQwDLozrdI10EHSi0_wPK8AE.U758K8ycQLh4pS-vRitbcHa_-mKafDFdSXnmtlqYhGwpjA4Zy4pAkXuUaA~771155a82121ca8bdafe275dbedcf5cb

Goldman Sachs Initiates Mineralys Therapeutics at Buy With $30 Price Target	Apr. 02	MT
Credit Suisse Adjusts Mineralys Therapeutics' Price Target to $37 From $38, Keeps Outperform Rating	23-08-08	MT
Credit Suisse Adjusts Mineralys Therapeutics' Price Target to $38 From $40, Keeps Outperform Rating	23-03-16	MT
Evercore ISI Starts Mineralys Therapeutics at Outperform	23-03-07	MT
Wells Fargo Starts Mineralys Therapeutics at Overweight With $27 Price Target	23-03-07	MT
Guggenheim Starts Mineralys Therapeutics at Buy With $32 Price Target	23-03-07	MT
BofA Securities Starts Mineralys Therapeutics at Buy With $39 Price Target	23-03-07	MT
Credit Suisse Starts Mineralys Therapeutics at Outperform With $40 Price Target, Says Potential Near-Term Partnership Could Boost Stock Value	23-03-07	MT
Stifel Starts Mineralys Therapeutics at Buy With $45 Price Target	23-03-07	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.52 USD

Average target price

33.5 USD

Spread / Average Target

+147.78%

High Price Target

45 USD

Spread / Highest target

+232.84%

Low Price Target

26 USD

Spread / Lowest Target

+92.31%